New paradigms for cancer drug discovery?

Cancer Biology and Therapy

Volumn 2, Issue 4, 2003, Pages 452-455

  Sager, Jason A ^a   Lengauer, Christoph ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Academic research; Cancer; Drug discovery

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; CLINICAL TRIAL; DRUG DESIGN; DRUG INDUSTRY; ECONOMICS; HUMAN; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; NEOPLASMS;

EID: 1142289993     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.4.448     Document Type: Article

References (19)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9:138-41 (Pubitemid 23098782)
2. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2:331-41. (Pubitemid 37328946)
3. Bardelli A, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300:949. (Pubitemid 36548874)
4. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643-9. (Pubitemid 29003936)
5. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003; in press.
6. Ma P, Zemmel R. Value of novelty? Nat Rev Drug Discov 2002; 1:571-2.
7. Franco RJ, Kaitlin KI. Beyond the Blockbuster. Pharmaceutical Executive. Nov 2002.
8. Hertzberg RP, Pope AJ. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000; 4:445-51.
9. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90:11693-7. (Pubitemid 24008705)
10. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001; 19:940-5. (Pubitemid 32947572)
11. Wolcke J, Ullmann D. Miniaturized HTS technologies - uHTS. Drug Discov Today 2001; 6:637-46. (Pubitemid 32567622)
12. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46:3-26. (Pubitemid 33653411)
13. Johnson JI, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-31. (Pubitemid 32522115)
14. Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother 1984; 20:1-20.
15. Buchdunger E, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-45.
16. Sim P, Gill J. in CMR International , 2002.
17. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. PharmacoEconomics 2002; 20:1-10. (Pubitemid 35397394)
18. Janssen PA. Drug research. Rev Med Brux 1980; 1:643-5.
19. Smith A. A call to arms for drug discoverers. Nat Rev Drug Discovery 2003; 2:335.